



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

## NEOVACS' ANNOUNCES THE SUCCESS OF ITS GENERAL MEETING OF SHAREHOLDERS

**Paris and Boston, March 12, 2018 - 6.00 am CET - Neovacs (Euronext Growth Paris: ALNEV)**, a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the approval by its shareholders of all the resolutions presented during its combined general meeting, which was held on second notice on March 12, 2018 at 9:30 am at the company's headquarters<sup>1</sup>.

Miguel Sieler, Chief Executive Officer of Neovacs said: "*We are delighted by the fruitful exchanges with our shareholders, as the Company is entering into an important phase of its development. We would like to reiterate that we are doing everything we can to achieve the objectives we have set to create value, and we would once again like to express our gratitude to our shareholders for the trust they place in us.*"

During the AGM, the company presented its objectives for 2018/2019, which assume the outcome of its clinical study in lupus with IFN $\alpha$  Kinoid is positive. The results should be known by June 2018. Based on the adopted resolutions, and subject to the positive outcome of this study, Neovacs intends to:

- Finalize discussions for a global partnership with the IFN $\alpha$  Kinoid in Lupus and DM according to the usual terms for this kind of agreement.
- Validate with the healthcare authorities the Lupus Phase III clinical program.
- Submit as agreed with our partner CKD an ODD request in South Korea.
- Pursue and complete the R&D programs currently underway, in particular with IFN $\alpha$ Kinoid.

Finally, all the convertible bonds issued on February 28, 2018,<sup>2</sup> have been converted into shares by their holders, prior to the general meeting, at the request of the company, thus making it possible to contribute to the quorum required by the law. This conversion resulted in the issue of 8,864,131 new shares immediately equal to the existing shares, in line with the previous announcement on February 28, 2018<sup>3</sup>.

### About Neovacs

Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN $\alpha$ -Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and

---

<sup>1</sup> Resolution no. 13 (Increase in share capital under the conditions set out in Article L. 3332-18 of the French Labor Code, with preferential subscription rights waived) which was presented to satisfy a legal obligation however, has not been approved. It is recalled that the Board of Directors, considering its approval not timely, had invited the general meeting to reject this draft resolution.

<sup>2</sup> Press release published by the Company on February 28, 2018.

<sup>3</sup> Cf. note 2 above

also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. [www.neovacs.fr](http://www.neovacs.fr)

**For more information on Neovacs, please visit [www.neovacs.fr](http://www.neovacs.fr)**

**Neovacs - Corporate Communications & Investors Relations**

**Charlène Masson**

Tel. + 33(0)1 53 10 93 00

[cmasson@neovacs.com](mailto:cmasson@neovacs.com)